Infarct Growth After Intravenous Tocilizumab in Adults With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy - ILLUMINATE

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 156 participants.

Also called NCT07870681

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 156 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07870681
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Denmark, Norway (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07870681. Randomized; quadruple masking; primary purpose treatment. Start 2026-09-21 (anticipated); primary completion 2029-01-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Infarct Growth After Intravenous Tocilizumab in Adults With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy - ILLUMINATE
Acronym
Illuminate
Condition
Acute Ischemic Stroke
Intervention (Drug)
Tociliuzumab
Intervention (Drug)
Placebo
Lead sponsor
Oslo University Hospital (class: other)
Collaborator
Copenhagen University Hospital, Rigshospitalet (class: other)
Collaborator
University Hospital, Akershus (class: other)
Collaborator
Aarhus University Hospital (class: other)
Collaborator
Aalborg University Hospital (class: other)
Collaborator
Odense University Hospital (class: other)

Record details

Record id
cardio:ct-nct07870681
Content hash
99d09b03c5fe3a8f34c428b3cdd84ce8fffc813261e513582291f381f8b9e642